Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354831 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT04354831 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 131 participants.
The verdict
NCT04354831, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
Interventions
- BIOLOGICAL anti-SARS-CoV-2 convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2020-05-11 |
| Est. Completion | 2021-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04354831
The ClinicalTrials.gov registry entry for NCT04354831 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anti-SARS-CoV-2 convalescent plasma is the first listed.
NCT04354831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04354831 about?
NCT04354831 is a clinical study titled "Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients". This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
What is the current status of trial NCT04354831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2020-05-11. Estimated completion is 2021-02-10.
What interventions are being tested in trial NCT04354831?
The interventions under investigation include: anti-SARS-CoV-2 convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04354831?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.